When was Savara Pharma founded?

Savara Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is Savara Pharma located?

Savara Pharma is headquartered in Austin, United States.

How many employees does Savara Pharma have?

As of Aug 31, 2026, the latest employee count at Savara Pharma is 125.

Is Savara Pharma a funded company?

Savara Pharma is a funded company, having raised a total of $67.8M across 14 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 08, 2009.

When was the latest funding round of Savara Pharma?

Savara Pharma's latest funding was a $***** Post IPO round on Dec 20, 2019, with participation from 3 investors.

What is the annual revenue of Savara Pharma?

Annual revenue of Savara Pharma is between $1M and $10M as on Dec 31, 2011

Where does Savara Pharma rank among its competitors?

Savara Pharma ranks 51st amongst 2550 active competitors, of which 864 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Savara Pharma?

Savara Pharma's top competitors include Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Savara Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Savara Pharma is a public company based in Austin (United States), founded in 2008 by Rob Neville. It operates as a Developer of therapeutics for rare respiratory diseases. Savara Pharma has raised $67.8M in funding from Austin Technology Incubator. The company has 2550 active competitors, including 864 funded and 638 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology.

Company Details

Developer of therapeutics for rare respiratory diseases. The company’s lead product is molgramostim nebulizer solution, which is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (aPAP).

Key Metrics

Founded Year

2008

Location

Austin, United States

Stage

Public

Total Funding

$67.8M in 14 rounds

Latest Funding Round

Post IPO, Dec 20, 2019, $*****

Investors

Austin Technology Incubator & 21 more

Ranked

51^st among 2550 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2011

Employee Count

125 as on Aug 31, 2026

Investment & Acquisitions

Serendex Pharmaceuticals

Similar Companies

X4 Pharmaceuticals & 166 more

Exit Details

Public

View Savara Pharma's full profile

Savara Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SAVARA INC CIN: 1160308 , United States, Active	Nov 30, 1995	$1M - $10M (As on Dec 31, 2011)	37 (As on Mar 31, 2023)	-
Savara Inc. CIN: 26-0456317001 , United States, Active	Dec 31, 2007	-	19 (As on Dec 31, 2021)	-

Savara Pharma got listed on Apr 27, 2017.

Click here to take a look at Savara Pharma's IPO in detail

Savara Pharma has raised a total funding of $67.8M over 14 rounds. Its first funding round was on Jun 08, 2009. Its latest funding round was a Post IPO round on Dec 20, 2019 for $*****. 3 investors participated in its latest round. Savara Pharma has 22 institutional investors.

Here is the list of recent funding rounds of Savara Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2019	5773895	Post IPO	1896673	3257129	5768866	2042581
Dec 04, 2017	5545974	Post IPO	5753920	5279622	9389069	Cystic Fibrosis Foundation
Feb 29, 2016	3332781	Series C	3586818	2511804	5956515	1896155

Access funding benchmarks and valuations. Sign up today!

View details of Savara Pharma's funding rounds and investors

The founders of Savara Pharma is Rob Neville. Matt Pauls is the CEO of Savara Pharma.

Here are the details of Savara Pharma's key team members:

Rob Neville: Former Founder of Savara Pharma.
Matt Pauls: CEO of Savara Pharma.
Contact Info: 1 email address

View details of Savara Pharma's Founder profiles and Board Members

Savara Pharma's employee count trend

Savara Pharma has 125 employees as of Aug 26. Here is Savara Pharma's employee count trend over the years:

Uncover Savara Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Savara Pharma include Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology. Here is the list of Top 10 competitors of Savara Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, Bain Capital Life Sciences ... & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
51st	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Bain Capital Life Sciences, Logos & 20 others	65/100